Zhang et al. [65] used amphoteric phosphorylcholine and chitosan to develop mimetic phosphorylcholine chitosan nanoparticles (PCCs-NPs) as a protein (msFGFR2c) delivery platform for the treatment of PF, which inhibited TGF-β1-induced α-SMA expression in fibroblasts, significantly reduced PF scores and collagen deposition, and significantly improved survival rates. This evidence concerns the gene TGFB1 and pemphigus foliaceus.